Stem cell research pioneer Geron Corporation, the first company to win approval from the Food and Drug Administration to conduct an embryonic stem cell trial on humans, will discontinue development of its stem cell programmes and instead focus on oncology, according to a 14 November announcement.
In the “current environment of capital scarcity and uncertain economic conditions,” said Geron’s CEO, John Scarlett, the company would channel its resources into advancing its Phase 2 clinical trials of imetelstat and GRN1005, two cancer drug candidates.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.